Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | PDE1A | P54750 | 2/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.30 |
| ▸ | PDE6A | P16499 | 1/20 | 0.30 |
| ▸ | PDE6B | P35913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25934710 | 0.82 | GAA (0.30) | GAA | |
| SCHEMBL22826020 | 0.78 | GAA (0.33) | GAACYP4F2CYP4A11 | |
| SCHEMBL22825973 | 0.77 | GAA (0.38) | GAACYP4F2CYP4A11 | |
| SCHEMBL31622729 | 0.77 | GAA (0.38) | GAACYP4F2CYP4A11 | |
| SCHEMBL24195697 | 0.74 | GAA (0.31) | GAACYP4F2CYP4A11 | |
| SCHEMBL18209744 | 0.71 | CYP4F2 (0.40) | GAACYP4F2CYP4A11 | |
| SCHEMBL21152701 | 0.69 | GAA (0.51) | GAACYP4F2CYP4A11 | |
| SCHEMBL30904946 | 0.68 | GAA (0.39) | GAACYP4F2CYP4A11 | |
| SCHEMBL21274624 | 0.67 | CYP4F2 (0.44) | CYP4F2CYP4A11 | |
| SCHEMBL13264542 | 0.67 | GAA (0.38) | GAACYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250109-A1 | MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | MCL1, BAK1, BCL2L1 | GAA 3823/4885CYP4F2 4338/4885CYP4A11 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.